Osimertinib (AZD9291)

For research use only. Not for use in humans.

製品コードS7297 別名：Mereletinib

CAS No. 1421373-65-0

Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

サイズ

価格(税別)

5mg	JPY 18100
10mg	JPY 24400
100mg	JPY 118200

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(237)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明

特性

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

ターゲット

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

体外試験

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. ^[2]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC-9/BRc1	M2mzO2Z2dmO2aX;uJGF{e2G7	NV3TPFR3PTBibl2=	M3HNcFI1KGh?	NHn5WXNFVVOR	MmjIbY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	M1TseFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|I2Lz5{NUS3O\|MzPTxxYU6=
PC-9/ERc1	NFmyZW5HfW6ldHnvckBCe3OjeR?=	NHj6fZE2OCCwTR?=	MnzENlQhcA>?	NUTlWZZyTE2VTx?=	MY\pcoR2[2W\|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?=	NVPpWHptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
VP-2	Mo\DSpVv[3Srb36gRZN{[Xl?	MlnmOVAhdk1?	NHr0PFEzPCCq	NUm2RW11TE2VTx?=	M1HPRolv\HWlZYOg[ZhxemW\|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN	NYLvTHZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/BRc1	M4TBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPuUms2OCCwTR?=	MUGxNEBl	Mn7TSG1UVw>?	MkDIbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm\|	M37i[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|I2Lz5{NUS3O\|MzPTxxYU6=
PC-9/ERc1	M4PXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLqOVAhdk1?	NF6xe\|cyOCCm	NY\pPVlPTE2VTx?=	NIX6bZFqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
VP-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TXUFUxKG6P	NVLQ[nY1OTBiZB?=	NX[zNnJFTE2VTx?=	NH3scZRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO=	Mmi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
PC9 GR4	MlWxSpVv[3Srb36gRZN{[Xl?	MW[wMVExKM7:TR?=	MYS3NkBp		NVr2[5ExcW6qaXLpeJPDqEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHHu[EBld3ewc4Ty[YFuKHOrZ37hcIlv\8Li	M{TScFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9	Mnm5SpVv[3Srb36gRZN{[Xl?	M4rrfVAuOTBizszN	MV23NkBp		M1e2SIlvcGmkaYTzJHdVKEWJRmKgZZQhdG:5IHPvcoNmdnS{YYTpc45{	M{G2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 GR4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXiwMVExKM7:TR?=	M3\BelczKGh?		NW[5e3RpcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2OE[zN{c,OjV7NEi2N\|M9N2F-
BAF3	M4TPWWZ2dmO2aX;uJIF{e2G7		Mnu5O\|IhcA>?		MmHOS2k2OCB;IECuNFAxOyEQvF2=	MmPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3	Mke3SpVv[3Srb36gZZN{[Xl?		MYi3NkBp		NHjQO2tIUTVyIE2gNE4xODB\|IN88US=>	M{S2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	MYLGeY5kfGmxbjDhd5NigQ>?		MX:3NkBp		NULE[4RHT0l3MDC9JFAvODBzIN88US=>	M3n2b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	NEjqN3JHfW6ldHnvckBie3OjeR?=		MknLO\|IhcA>?		MkDRS2k2OCB;IECuNFAyKM7:TR?=	Mn7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	MljYSpVv[3Srb36gZZN{[Xl?		NGPiTXM4OiCq		NY\yR2lPT0l3MDC9JFAvODB{IN88US=>	M3XD[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	NWO3TpZ7TnWwY4Tpc44h[XO\|YYm=		MmLrOEBp		M2jqZWVEPTBiPTCwMlAxOiEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	NIfSb4pHfW6ldHnvckBie3OjeR?=		M2\xXVMhcA>?		MYLJR\|UxKD1iMD6wNFI2KM7:TR?=	NHfRb4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
H1975	M4\pfGZ2dmO2aX;uJIF{e2G7		NEDCcGo{KGh?		NHnRVYdKSzVyIE2gNE4xODJ3IN88US=>	M1qzfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN\|gzQTxxYU6=
H3255	MVvGeY5kfGmxbjDhd5NigQ>?		MYqzJIg>		M4\1dGlEPTBiPTCwMlAxPDFizszN	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2M{O4NlkoRjJ5NEOzPFI6RC:jPh?=
NCI-H1975	NGrCNppHfW6ldHnvckBie3OjeR?=		MXu3NkBp		Mn7YS2k2OCB;IECuNFA2KM7:TR?=	NYnxcWhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MnKzO\|IhcA>?		M3PI[mlEPTBiPTCwMlAxPjVizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975	NXL0bYdXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NV\0bVJ6PzJiaB?=		NYPGOmhoUUN3MDC9JFAvODFyNTFOwG0>	M2W0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
Sf21	MUnGeY5kfGmxbjDhd5NigQ>?				NFracIRKSzVyIE2gNE4xOTJizszN	NGDGVZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
PC9-DRH	MoWxSpVv[3Srb36gZZN{[Xl?		MUOyJIg>		MVPJR\|UxKD1iMD6wNVMh\|ryP	M2rROVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
BAF3	MkO3SpVv[3Srb36gZZN{[Xl?		M4X3blczKGh?		NVjRdHYzT0l3MDC9JFAvODF\|IN88US=>	NV:wcItiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	MnTHSpVv[3Srb36gZZN{[Xl?		MnTVPVYhcA>?		MYLFR\|UxKD1iMD6wNVQh\|ryP	NWT2U2tLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlUzPjlpPkK4NlI2OjZ7PD;hQi=>
HCC827	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NIXWZVE6PiCq		NEjWRpJGSzVyIE2gNE4xOTRizszN	M3:y[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
NCI-H1975	M3S3R2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MoPjPVYhcA>?		M1ezZWVEPTBiPTCwMlAyPCEQvF2=	NGLRN\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	M1PpSmZ2dmO2aX;uJIF{e2G7		M4T0U\|IhcA>?		NXrVToxoUUN3MDC9JFAvODF3IN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
H1975	NYnobnB6TnWwY4Tpc44h[XO\|YYm=		MU[yJIg>		MlvDTWM2OCB;IECuNFE2KM7:TR?=	NYDIWmpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlgzPTNpPkK2PVY5OjV\|PD;hQi=>
PC9	M1\rWmZ2dmO2aX;uJIF{e2G7		NWDCdIZTOiCq		MXjJR\|UxKD1iMD6wNVch\|ryP	M{HvfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[4NlU{Lz5{Nkm2PFI2OzxxYU6=
NCI-H1975	NXnYOZhRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MmrYO\|IhcA>?		MVzJR\|UxKD1iMD6wNVkh\|ryP	M3WzN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O\|c{Lz5{OUS2Olc4OzxxYU6=
NCI-H1975	NWT6eGZTTnWwY4Tpc44h[XO\|YYm=		NVntOmo1QTZiaB?=		NGjS[XZGSzVyIE2gNE4xOTlizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
NCI-H1975	Mk\pRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NXHiU5FMQTZiaB?=		MnSzSWM2OCB;IECuNFE6KM7:TR?=	NVT2W21YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NFM6QTFpPkK4OlA{QTlzPD;hQi=>
NCI-H1975	NH\ye45CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MVu3NkBp		M{DWV2lEPTBiPTCwMlAyQSEQvF2=	MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN\|QxRC:jPh?=
HCC827	NUP5UVFpTnWwY4Tpc44h[XO\|YYm=		MVuyJIg>		NFvlUlFKSzVyIE2gNE4xOjNizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
NCI-H1975	NYHvXIlySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NWHERZBFPzJiaB?=		NUL5SYlIUUN3MDC9JFAvODJ\|IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmyOkc,Ojl3M{S5NlY9N2F-
PC9	MoDsR5l1d3SxeHnjbZR6KGG\|c3H5		NUOwT5B5PzJiaB?=		NVHHcWwxT0l3MDC9JFAvODJ\|IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	M2HhTmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYPBRlFXPzJiaB?=		MVHHTVUxKD1iMD6wNlQh\|ryP	M4jSXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
HCC827	NV3Xfod3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NXPuToJtPzJiaB?=		NWPnZlRtUUN3MDC9JFAvODJ3NDFOwG0>	NHz5VIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O\|YzPzJ:L3G+
HCC827	NWLmeYx6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M2XkWVczKGh?		NHT3VGtKSzVyIE2gNE4xOjdizszN	NEPXPJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
HCC827	NHflZ4ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1G4ZlczKGh?		NUOz[ZpHUUN3MDC9JFAvODJ5IN88US=>	NEnzb5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
NCI-H1975	M3nkd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NULvZml7PzJiaB?=		NVLw[IN1UUN3MDC9JFAvODNizszN	MkDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{O1O\|koRjJ6MEOzOVc6RC:jPh?=
H3255	MlfaSpVv[3Srb36gZZN{[Xl?		NVy4R\|ZFPzJiaB?=		MWrHTVUxKD1iMD6wN\|Mh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255	Mmf4SpVv[3Srb36gZZN{[Xl?		M4XY[VIhcA>?		NGXuUoxKSzVyIE2gNE4xOzZizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
NCI-H1975	M2HKdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NIrET4o4OiCq		M4jr[mlEPTBiPTCwMlA1OSEQvF2=	NWnHVWxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|AyQTJpPkK5O\|MxOTl{PD;hQi=>
NCI-H1975	MVjGeY5kfGmxbjDhd5NigQ>?		MkLlNUBp		NHXhXY9KSzVyIE2gNE4xPDFizszN	NX\he\|NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
BAF3	NVm2eXRCTnWwY4Tpc44h[XO\|YYm=		M2PoVlQhcA>?		NF\Me2JGSzVyIE2gNE4xPDNizszN	MliyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NH7vN4s4OiCq		M2fFUmlEPTBiPTCwMlA1PzJizszN	NXXne5JMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
NCI-H1975	NGW0VFlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1jCc\|czKGh?		MlL4TWM2OCB;IECuNFUzKM7:TR?=	NWfCUXBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|E3OzlpPkK3NVMyPjN7PD;hQi=>
PC9	MmrCSpVv[3Srb36gZZN{[Xl?		MkjjNkBp		NVHUcFhVUUN3MDC9JFAvODV4IN88US=>	Ml\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
NCI-H1975	M4fxPWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkDHO\|IhcA>?		MXjJR\|UxKD1iMD6wOkDPxE1?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
HCC827	NV\ySlFiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=				MYLJR\|UxKD1iMD6wOlE3KM7:TR?=	NVG5VXdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
NCI-H1975	NFnxdJhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=				NV[5eYN3UUN3MDC9JFAvODZ5IN88US=>	M2\nelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
HaCaT	MYHGeY5kfGmxbjDhd5NigQ>?		NUPDSJdKOyCq		NXXz[m5WUUN3MDC9JFAvODd\|NzFOwG0>	NF7adJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
NCI-H1975	MnjBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MX[3NkBp		NF7JcJpKSzVyIE2gNE4yOyEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431	MlflSpVv[3Srb36gZZN{[Xl?		NF7GfpEyKGh?		M{S4TmlEPTBiPTCwMlE1OSEQvF2=	NVTwZohJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A549	M3TBXmZ2dmO2aX;uJIF{e2G7				MlXCTWM2OCB;IECuNVUh\|ryP	NHvKNGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
Calu3	NFrNd2tEgXSxdH;4bYNqfHliYYPzZZk>		MV63NkBp		M4eyWWdKPTBiPTCwMlI3PCEQvF2=	M3TMNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
Sf9	MkPqSpVv[3Srb36gZZN{[Xl?		MmfLNlAhdWmwcx?=		NE\1SplKSzVyIE2gNE4zPzhizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR6MkG1NUc,Ojh2OEKxOVE9N2F-
BAF3	MoizSpVv[3Srb36gZZN{[Xl?		NGTCWYg4OiCq		Mm\LS2k2OCB;IECuN{DPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	MXXGeY5kfGmxbjDhd5NigQ>?		NIfRVoI4OiCq		NVP0fIIzT0l3MDC9JFAvOzFizszN	NY\STJM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H460	NYHWWmwySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NX;HbmM2PzJiaB?=		M4fNd2lEPTBiPTCwMlQyPTlizszN	NXLlO\|h[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
LoVo	NIPjdHlHfW6ldHnvckBie3OjeR?=		M1:5d\|IhcA>?		NHz0[XhKSzVyIE2gNE41QCEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo	MYnGeY5kfGmxbjDhd5NigQ>?		MoOwNkBp		MnHyTWM2OCB;IECuOFgh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NkK2O{c,Ojd7OU[yOlc9N2F-
A549	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MXy3NkBp		M{fVWWlEPTBiPTCwMlQ5PiEQvF2=	NHPrOY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O\|YzPzJ:L3G+
BAF3	MXjGeY5kfGmxbjDhd5NigQ>?		M2nuTVczKGh?		M2LjXGdKPTBiPTCwMlUh\|ryP	M1XtbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A549	NXnxbWRrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M{jwTFczKGh?		NYfvW\|d[UUN3MDC9JFAvPTNizszN	M4nZb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O\|c{Lz5{OUS2Olc4OzxxYU6=
A549	MVHDfZRwfG:6aXPpeJkh[XO\|YYm=		NEmwdVM4OiCq		M33MfGlEPTBiPTCwMlU{KM7:TR?=	M13PcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN\|QxLz5{OUi1N\|M1ODxxYU6=
BAF3	MU\GeY5kfGmxbjDhd5NigQ>?		MmeyO\|IhcA>?		MnvtS2k2OCB;IECuOVUh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	M13MPWZ2dmO2aX;uJIF{e2G7		Mn3NO\|IhcA>?		NU\Gc5lkT0l3MDC9JFAvPTZizszN	M3frflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HEK293	MnrrSpVv[3Srb36gZZN{[Xl?				NHf2OZNKSzVyIE2gNE42PyEQvF2=	M2rhUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
BAF3	NHL1e4VHfW6ldHnvckBie3OjeR?=		M2KyRVczKGh?		MnPrS2k2OCB;IECuOVkh\|ryP	M1SySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A431	NFfvXZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=				NUn3VYkyUUN3MDC9JFAvPjF3NjFOwG0>	NV;ybHhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
HT-29	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		NXXjO5pEPzJiaB?=		Mn7YTWM2OCB;IECuOlUh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
A431	MYjGeY5kfGmxbjDhd5NigQ>?		Mo\SPVYhcA>?		NX;ub453TUN3MDC9JFAvPjZ5IN88US=>	NVftZWhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlUzPjlpPkK4NlI2OjZ7PD;hQi=>
A431	NG\6WnJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NVvobmhzQTZiaB?=		MWPFR\|UxKD1iMD62O{DPxE1?	NIXQXXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
A431	M4HNU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NGPYTmc4OiCq		NUHmeI5sUUN3MDC9JFAvPjh3IN88US=>	NVfRRXIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A431	M1GzVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MYm5OkBp		NUL1TGN5TUN3MDC9JFAvPyEQvF2=	M2XtSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkCzPVkyLz5{OE[wN\|k6OTxxYU6=
A549	M4nGd2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MYO3NkBp		NVr6eHVLUUN3MDC9JFAvQDdizszN	NHLsNlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
A431	MorlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MlfGO\|IhcA>?		NVHqRYtTUUN3MDC9JFAvQDl\|IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MU[zPUc,OjdzM{G2N\|k9N2F-
BA/F3	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MkS2O\|IhcA>?		MlfoTWM2OCB;IEGg{txO	M4K4V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BAF3	NGXNOoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4L5blczKGh?		M2XMOWdKPTBiPTCxMlIh\|ryP	MlnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H2122	Ml3xSpVv[3Srb36gZZN{[Xl?		NFHxc4w4OiCq		M4rvNmdKPTBiPTCxMlIh\|ryP	M{L6flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A431	MnnzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NH34b5I4OiCq		NXnr[VJSUUN3MDC9JFEvOjRizszN	M1\TdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
A431	NX:xdJJ6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NFvCW3c4OiCq		NU\RZ4w2UUN3MDC9JFEvOjZizszN	NVn1VZdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|AyQTJpPkK5O\|MxOTl{PD;hQi=>
A431	M{Tw[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MoTjO\|IhcA>?		MXLJR\|UxKD1iMT62NFQh\|ryP	NFnmSIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzN\|U4QSd-MkiwN\|M2Pzl:L3G+
A549	M1;TWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MUK5OkBp		M{D2dmVEPTBiPTCxMlg{KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
CHL	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1rlWVczKGh?		NUjGSGJoT0l3MDC9JFIvQSEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1355	MorlSpVv[3Srb36gZZN{[Xl?		NHnMbFk4OiCq		MnXyS2k2OCB;IEOg{txO	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1703	MW\GeY5kfGmxbjDhd5NigQ>?		M1vNOVczKGh?		NHTtTWtIUTVyIE2gN{42KM7:TR?=	NUnFOWVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A549	M3fWVWZ2dmO2aX;uJIF{e2G7		MV23NkBp		NYWxW2tbT0l3MDC9JFMvPSEQvF2=	NUHremJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
CHO	NY\1PIRCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUS3NkBp		NFS4d2JIUTVyIE2gOE4zKM7:TR?=	NULLcpZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	NH7Zd41CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NVLwZ5psPzJiaB?=		NUi0VItWUUN3MDC9JFQvPjFizszN	MkHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BAF3	NXP4[JdUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NWHDdnZxPzJiaB?=		Ml\xTWM2OCB;IEWuNVUh\|ryP	NY\pPWZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BEAS2B	NHrJXFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NIDPcoI4OiCq		M1X5cGlEPTBiPTCxOE46KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975	MWrGeY5kfGmxbjDhd5NigQ>?		NXfEeFNzOiCq		MknxTWM2OCB;IEG1JO69VQ>?	NEewNGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
PC9	NHK3VI9HfW6ldHnvckBie3OjeR?=		MUWyJIg>		MoW5TWM2OCB;IEG3JO69VQ>?	NV3MT5AzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
LoVo	M1zDcmZ2dmO2aX;uJIF{e2G7		NVO0bnJCOiCq		MmDFTWM2OCB;IES4NEDPxE1?	MmP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975	NHfWdYZCdnSrdIXtc5Ih[WO2aY\peJkh[XO\|YYm=				M2j2OWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOi53IH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s	NH7JW409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
rat hepatocytes	M{\iVGZ2dmO2aX;uJIF{e2G7				MmGwTY51emmwc3njJINt\WG{YX7j[UBqdiC{YYSgbIVx[XSxY4n0[ZMhdWWjc4Xy[YQheGW{IEGwK\|Yh[2WubIO=	Ml3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
human hepatocytes	MnLCSpVv[3Srb36gZZN{[Xl?				MVzJcpRzcW6\|aXOgZ4xm[XKjbnPlJIlvKGi3bXHuJIhmeGG2b3P5eIV{KG2nYYP1doVlKHCncjCxNEc3KGOnbHzz	NXXCRnQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
NCI-H1975	MVPBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				M2G5dGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhPSCvZz;r[{9l[XluIIDvJJFlKG[xcjC3JIRigXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	M13xUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975	MWXGeY5kfGmxbjDhd5NigQ>?				NHSxdZRU\WynY4Tpeol1gSCrbnTlfEwhemG2aX:gc4YhUUN3MDDmc5IhTUeIUjDUO\|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHSxIFnDOVAh\m:{IIfpcIQhfHmyZTDFS2ZTKGW6cILld5NqdmdiaIXtZY4hSTR\|MTDj[Yxtew>?	M2WwN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
NCI-H1975	M3vNOGFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				MkXuRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWiCWN{mwUU9NQDV6UjDkc5VjdGVibYX0ZY51KGW6cILld5NqdmdiaIXtZY4hVkOLLVixPVc2KGOnbHzzJJhmdm:pcnHmeIVlKGmwIFLBUGIw[yCjdHj5cYlkKG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNVAhdWdxa3esJJBwKGKrZDDmc5IhOjFiZHH5dy=>	NWfvNnNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|AyQTJpPkK5O\|MxOTl{PD;hQi=>
HCC827	NHPFfndCeG:ydH;zbZMh[XO\|YYm=				NFSxXWpKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIViemy7IHHwc5B1d3SrYzDj[YxteyCjdDCzJJVOKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYuTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5JEhTfmJiPTCxMlM1LSl?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
HCC827	MYjBdI9xfG:\|aYOgZZN{[Xl?				Mkn1TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0Ok1CPzVyIHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDsZZRmKGGyb4D0c5Rq[yClZXzsd{BifCB\|IIXNJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[tSmlVSy:ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7IDjSeoIhRSB{Nz6xOEUq	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
A549	NVrQOVlsTnWwY4Tpc44h[XO\|YYm=				MnzxV4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhcHWvYX6gRVU1QSClZXzsd{BmgHC{ZYPzbY5oKHerbHSteJlx\SCHR1\SM2suWmG\|IH31eIFvfCC2bzDJR\|UxKG[xcjDoeY1idiCQQ1mtTFE6PzViY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUL2S3PVBOKGSxdXLs[UBufXSjboS=	NH3yfYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
HCC827	NIPjXWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1\jTlczKGh?		MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{iyO{Bk\WyuczDheEAyKHWPIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbB?=	MoTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO\|IoRjJ7NUe2NlczRC:jPh?=
BAF3	NFL0TIdHfW6ldHnvckBie3OjeR?=		NXTodIhKOiCq		M1TxZmlvcGmkaYTpc44hd2ZiRVfGVkBVPzlyTT;MPFU5Wi:FN{m3V{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHNWmwZIXj[YQhemWlZYD0c5IheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gN{B2VSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M{CzUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
BAF3	MoLqSpVv[3Srb36gZZN{[Xl?		MVOyJIg>		M1\P[WlvcGmkaYTpc44hd2ZiRVfGVkAyQURxVEe5NG0wSzd7N2OgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFXHSk1qdmS3Y3XkJJJm[2WydH;yJJBpd3OyaH;yfYxifGmxbjDheEAyKHSxIEOgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBGT0Zic4TpcZVt[XSrb36g[o9zKDF3IH3pcpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NHzo[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
NCI-H1975	MlTFRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				MY\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhgGWwb3fyZYZ1\WRiaX6gV3RQS0tvRn;4clFvfS:QaoWgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHfyc5d1cCCjdDCyNEBu\y:tZz;kZZktKHCxIIHkJIZweiBzNDDkZZl{KHKnbHH0bZZmKHSxIIXueJJm[XSnZDDjc451em:u	NEjadW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVIyQSd-MkizPVUzOTl:L3G+
Caco2	MlK1SpVv[3Srb36gZZN{[Xl?		NUjh[mxNOiCq		MlrESYZndHW6IILheIlwKG:oIHHwdIFz\W62IIDldo1m[WKrbHn0fUBnem:vIHLhd49t[XSncnHsJJNq\GVidH:gZZBq[2GuIIPp[IUhd3[ncjDhdIlk[Wxic3nk[UB1dyCkYYPvcIF1\XKjbDDzbYRmKG:4ZYKgbY4hcHWvYX6gR4FkdzJiY3XscJMh[XRiNTD1UUBqdmO3YnH0[YQh\m:{IEKgbJJ{	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
A431	M{G3[mZ2dmO2aX;uJIF{e2G7				MWTT[Yxm[3Srdnn0fUBz[XSrbzDv[kBGSzVyIH\vdkBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKgeI8hTUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTNUx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ>	NHiyOJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
Caco2	M2n0SGZ2dmO2aX;uJIF{e2G7		MV6yJIg>		Ml65RZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{BieGmlYXygeI8h[mG\|b3zheIVz[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
Caco2	MXzGeY5kfGmxbjDhd5NigQ>?		MUeyJIg>		Mkf1RZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{Bj[XOxbHH0[ZJidCC2bzDhdIlk[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN?	M2nadVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
NCI-H1975	Mn\RSpVv[3Srb36gZZN{[Xl?		NEmw[Vg1KGh?		NHLvdnBKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KGmwIHj1cYFvKE6FST3INVk4PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRYt1KHCqb4PwbI9zgWyjdHnvckBifCCWaIKzNFgwW2W{NEezJJNqfGViYYSgNUB2VSCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NIntPFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	M2fSZ2Z2dmO2aX;uJIF{e2G7		M2nicVQhcA>?		MXPJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975	MnrKRZBweHSxc3nzJIF{e2G7		NX7OcmZnPDhiaB?=		NEnDcIJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQh[XO\|ZYPz[YQh[XNiY3HzdIF{\TNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	MnLSRZBweHSxc3nzJIF{e2G7		MV:0PEBp		MnX5TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCvdYThcpQh[XO\|ZYPz[YQh[XNiY3HzdIF{\S1\|IHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	M2fU[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
PC9	MVHBdI9xfG:\|aYOgZZN{[Xl?		NIPFUIY1QCCq		M{jhXmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H3255	M13pOmFxd3C2b4Ppd{Bie3OjeR?=		NYG2e\|dXPDhiaB?=		M{HoNWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSEOyOVUh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIhdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NCI-H1975	NVnv[HRMSXCxcITvd4l{KGG\|c3H5		MnuyOFghcA>?		MXTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5Wi:WN{mwUUBufXSjboSgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZTDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[y=>	NHm2RXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9	M3XhPWFxd3C2b4Ppd{Bie3OjeR?=		NEDaTWM1QCCq		NFjVUGdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	NVnUUY1MSXCxcITvd4l{KGG\|c3H5		M1jGO\|Q5KGh?		NHfXdVBKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDlfI9vKDF7IHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDQRXJRKGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK\|IHL5JIludXWwb3Lsc5R1cW6p	Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H3255	NU[5bVN5SXCxcITvd4l{KGG\|c3H5		Ml\4OFghcA>?		MULJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh\|MkW1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	M{P5dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	M2nwWGZ2dmO2aX;uJIF{e2G7				MWLT[Yxm[3Srdnn0fUBz[XSrbzDv[kBKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEB1dyCLQ{WwJIZweiCqdX3hckBCPDNzIHPlcIx{KGijcnLvdolv\yC5aXzkMZR6eGViRVfGVi=>	NIPKU\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
human hepatocytes	NFPX[HdHfW6ldHnvckBie3OjeR?=				M1rFZmlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5iaIXtZY4hcGWyYYTvZ5l1\XNiYYPz[ZN{\WRicHXyJI1qdGyrb36gZ4VtdHN?	NVHj[Iw1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
rat hepatocytes	NIe5N2dHfW6ldHnvckBie3OjeR?=				M37WWWlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5icnH0JIhmeGG2b3P5eIV{KGG\|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{	MlfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
A549, NCI-H1975	Ml[xSpVv[3Srb36gZZN{[Xl?				MmH4V4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhTUeILYP0bY12dGG2ZXSge4lt\CC2eYDlJGVITlJiaX6gbJVu[W5iQUW0PUBk\WyuczD0c{BKSzVyIH\vdkBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{	NFzq[3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
A549, PC9	MUjGeY5kfGmxbjDhd5NigQ>?				MlK4V4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhTUeILYP0bY12dGG2ZXSge4lt\CC2eYDlJGVITlJiaX6gbJVu[W5iQUW0PUBk\WyuczD0c{BKSzVyIH\vdkBGT0[UIHTlcIV1cW:wIH31eIFvfCCrbjDoeY1idiCSQ{mgZ4VtdHN?	M1PsWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
HCC827	MX;BdI9xfG:\|aYOgZZN{[Xl?				NVz2UFJEUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO\|UxKGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCnYYLsfUBieG:ydH;0bYMh[2WubIOgZZQhOyC3TTDh[pRmeiB{NDDodpMh[nliQX7u[ZhqdiCYLV\JWGMweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgSBqUo\iJF0hOS5\|NDD0c{AyNjZ5JTm=	M3;VPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN\|QxLz5{OUi1N\|M1ODxxYU6=
NCI-H1975	NH3XS3JHfW6ldHnvckBie3OjeR?=				NVLWTGM3UW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKEWJRj3zeIlufWyjdHXkJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCjdDCxJJRwKDFyMDDuUUBjgSCZZYP0[ZJvKGKub4SgcYV1cG:m	MnvHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7ME[xNVQoRjJ7OUC2NVE1RC:jPh?=
A431	Mn\kSpVv[3Srb36gZZN{[Xl?				MVnT[Yxm[3Srdnn0fUBz[XSrbzygdoF1cW9iSVO1NEBnd3JiaIXtZY4hSTR\|MTDj[YxteyCxdnXy[ZhxemW\|c3nu[{B4cWymLYT5dIUhTUeIUjD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNM2w5PTiUIH31eIFvfA>?	M{G3OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxOlM6Lz5{N{GzNVY{QTxxYU6=
PC9	NH\NTJVCdnSrdIXtc5Ih[WO2aY\peJkh[XO\|YYm=				MUjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBi[3SrdnH0bY5oKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyIH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
A431	MYHBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				NGG4S3hCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhPSCvZz;r[{9l[XluIIDvJJFlKG[xcjC3JIRigXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MmLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	p-EGFR / p-AKT / p-ERK; PubMed: 28416483 Cancer Res PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib. ABCB1; PubMed: 27649127 Molecules The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.	28416483 27649127
Growth inhibition assay	Cell viability; PubMed: 31043587 Cell Death Dis Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. P < 0.05, P < 0.01, **P < 0.005 by t-test.	31043587
Immunofluorescence	Ki67 / γH2AX / p16; PubMed: 29212784 EMBO Mol Med PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. P ≤ 0.01, *P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.	29212784

体内試験

AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. ^[2]

お薦めの試験操作（参考用のみ）

動物試験： ^[2]	- 合併動物モデル： Mice bearing PC9 and H1975 xenograft tumors 投薬量： ~5 mg/kg 投与方法： p.o. (参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	99 mg/mL (198.15 mM) warming
	Water	Insoluble
	Ethanol	'43 mg/mL warmed '43
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O 混合させたのち直ちに使用することを推奨します。	7.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Osimertinib (AZD9291) SDFをダウンロードする

分子量	499.61
化学式	C₂₈ H₃₃ N₇ O₂
CAS No.	1421373-65-0
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	Mereletinib
Smiles	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02841579	Completed	Drug: Osimertinib	Non-Small Cell Lung Cancer	MedSIR\|AstraZeneca	August 2016	Phase 2
NCT02771314	Unknown status	Drug: AZD9291	Non Small Cell Lung Cancer	Hellenic Oncology Research Group	August 2 2016	Phase 2
NCT02529995	Completed	Drug: AZD9291 40 mg\|Drug: AZD9291 80 mg	Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive	AstraZeneca	August 24 2015	Phase 1
NCT02491944	Completed	Drug: AZD9291\|Drug: [14C]AZD9291	Oncology	AstraZeneca	July 2015	Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?
回答：
Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFRシグナル伝達経路

相関EGFR製品

Erlotinib (OSI-774)

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B)

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

研究分野別

製品類型

Osimertinib (AZD9291)

文献中Selleckの製品使用例(237)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Osimertinib (AZD9291) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技術サポート

よくある質問（FAQ）

EGFRシグナル伝達経路

相関EGFR製品